Sign Up to like & get
recommendations!
1
Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2020-059
Abstract: Autologous T cells engineered to target the MAGE-A4 cancer testis antigen successfully shrank a wide range of solid tumors with a manageable toxicity profile. In a phase I trial, the therapy, ADP-A2M4, showed the most…
read more here.
Keywords:
targeting mage;
shrink tumors;
mage shrink;
mage ... See more keywords